Cardioprotection thread, page-206

Have come here after a recommendation from a colleague.
Interesting thread. I'll need to spend some time studying this as I don't understand yet how the bisantrene drug is being positioned in the modern paradigm and am unfamiliar with the evidence for this drug.
Is it really "cardioprotective" outside in vitro/animal studies? or is it that it's just less toxic than standard athracyclines. Things have moved on substantially in the 30-40 years since the phase3 breast cancer trial referred to on the company website, the drug came out quite a bit worse for response rate against doxorubicin but no cases of heart failure it's true. But then better screening for risk , newer markers, availability of echocardiography etc and newer drugs like the liposomal anthracyclines (less cardiotoxic) may have changed the landscape.